The Study of Atherosclerosis With Ramipril and Rosiglitazone
Atherosclerosis, Impaired Glucose Tolerance, Isolated Impaired Fasting Glucose
About this trial
This is an interventional prevention trial for Atherosclerosis focused on measuring atherosclerosis, carotid artery, ramipril, rosiglitazone, impaired glucose tolerance, impaired fasting glucose, diabetes prevention
Eligibility Criteria
Inclusion Criteria: impaired glucose tolerance (FPG < 7 mmol/L or 126 mg/dL & 2hr PG between 7.8-11.0 mmol/l [140-199 mg/dl] after a 75 g OGTT impaired glucose tolerance (FPG≥ 6.1 mmol/l [110 mg/dl]) and no diabetes (i.e. a FPG < 7.0 mmol/l [126 mg/dl]) a technically adequate baseline carotid ultrasound examination Exclusion Criteria: current use of an ACE-inhibitor (ACE-I) or thiazolidinedione (TZD) known hypersensitivity to ACE-I prior use of anti-diabetic medications 9with the exception of during pregnancy) use of systemic glucocorticoids or niacin congestive heart failure or EF < 40% existing cardiovascular disease (previous MI, stroke, angina, uncontrolled hypertension) diabetes renal or hepatic disease major illness use of another experimental drug pregnant or unwilling to use reliable contraception major psychiatric disorder diseases that affect glucose tolerance unwillingness to be randomized or sign informed consent known uncontrolled substance abuse inability to communicate with research staff